LakeShore Biopharma Co., Ltd (LSB)

NASDAQ: LSB · IEX Real-Time Price · USD
0.510
+0.010 (2.00%)
Jul 19, 2024, 9:59 AM EDT - Market open
2.00%
Market Cap 100.76M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 188.33M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,244
Open 0.535
Previous Close 0.500
Day's Range 0.510 - 0.535
52-Week Range 0.350 - 1.500
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 13, 2024

About LSB

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 773
Stock Exchange NASDAQ
Ticker Symbol LSB
Full Company Profile

Financial Performance

In 2022, LSB's revenue was 687.20 million, an increase of 36.63% compared to the previous year's 502.95 million. Losses were -421.46 million, 14.7% more than in 2021.

Financial numbers in CNY Financial Statements

News

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

GAITHERSBURG, Md. , July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, devel...

14 days ago - PRNewsWire

YS Biopharma Announces Name Change to LakeShore Biopharma

GAITHERSBURG, Md. , May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

2 months ago - PRNewsWire

YS Biopharma Announces Results of Extraordinary General Meeting

GAITHERSBURG, Md. , May 21, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

2 months ago - PRNewsWire

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

2 months ago - PRNewsWire

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

GAITHERSBURG, Md. , April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

2 months ago - PRNewsWire

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

GAITHERSBURG, Md. , April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

3 months ago - PRNewsWire

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

GAITHERSBURG, Md. , April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

3 months ago - PRNewsWire

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

GAITHERSBURG, Md. , April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

3 months ago - PRNewsWire

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

GAITHERSBURG, Md. , April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

3 months ago - PRNewsWire

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

GAITHERSBURG, Md. , April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

3 months ago - PRNewsWire

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

GAITHERSBURG, Md. , March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

4 months ago - PRNewsWire

YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

GAITHERSBURG, Md. , Feb. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

5 months ago - PRNewsWire

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

GAITHERSBURG, Md. , Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

5 months ago - PRNewsWire

Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the "Company" or "YS") (NASDAQ: YS) (the "Convening Shar...

5 months ago - PRNewsWire

YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

GAITHERSBURG, Md. , Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

5 months ago - PRNewsWire

YS Biopharma Announces Appointment of New Directors

GAITHERSBURG, Md. , Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

5 months ago - PRNewsWire

YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.

GAITHERSBURG, Md. , Feb. 12, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

5 months ago - PRNewsWire

YS Biopharma Announces US$40 Million Private Placement Financing

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

5 months ago - PRNewsWire

Shareholders of YS Biopharma Announce an Extraordinary General Meeting

BEIJING , Feb. 8, 2024 /PRNewswire/ -- Shareholders of YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...

5 months ago - PRNewsWire

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024

GAITHERSBURG, Md. , Jan. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

6 months ago - PRNewsWire

YS Biopharma Announces Changes to its Board Committees

GAITHERSBURG, Md. , Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.

6 months ago - PRNewsWire

YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting

GAITHERSBURG, Md. , Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.

7 months ago - PRNewsWire

YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023

GAITHERSBURG, Md. , Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.

7 months ago - PRNewsWire

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

GAITHERSBURG, Md. , Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.

8 months ago - PRNewsWire

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.

9 months ago - PRNewsWire